Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Nab-paclitaxel in Sensitive and Refractory Relapsed Small Cell Lung Cancer (Nabster Study)

NCT03219762 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.

NCT NCT03219762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03219762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Nab-paclitaxel in Sensitive and Refractory Relapsed Small Cell Lung Cancer (Nabster Study)
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Phase
Phase 2
Overall status
Unknown status
Start date
February 7, 2017
Completion date
January 31, 2019
Enrollment
65 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer